Status:
ACTIVE_NOT_RECRUITING
Efficacy and Safety Study of DURVALUMAB Maintenance in Patients With Stage III Non-Small Cell Lung Cancer
Lead Sponsor:
University Hospital, Brest
Conditions:
Bronchial Cancer
Eligibility:
All Genders
18-99 years
Brief Summary
The aim of this study is to evaluate the real-life efficacy of durvalumab treatment in consolidation after radio-chemotherapy.
Detailed Description
Immune checkpoint inhibitors (ICIs) such as anti-PD-1/PD-L1 have revolutionized the field of immuno-oncology, inducing significant and durable responses in patients with all types of tumor, and in par...
Eligibility Criteria
Inclusion
- Patients with unresectable locally advanced non-small-cell lung cancer (stages II, IIIA, IIIB and IIIC) responding to or stable after concomitant or sequential platinum-based radiochemotherapy and having received durvalumab consolidation therapy
- Minimum radiotherapy dose of 54 Gy to 66 Gy
- Age greater than or equal to 18 years
- WHO 0-1
- Non-opposition of living patients formulated
Exclusion
- Age \< 18 years.
- Refusal to participate
- Patients under legal protection (curatorship, guardianship, etc.)
Key Trial Info
Start Date :
June 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 30 2024
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06564870
Start Date
June 1 2021
End Date
December 30 2024
Last Update
August 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Brest
Brest, France, 29609